Sodium–glucose cotransporter 2 inhibitor‐induced euglycaemic diabetic ketoacidosis in heart failure with preserved ejection fraction

Sodium–glucose cotransporter 2 inhibitor‐induced euglycaemic diabetic ketoacidosis in heart failure with preserved ejection fraction

Abstract The number of patients receiving sodium–glucose cotransporter 2 inhibitors (SGLT2is), especially those with heart failure, is increasing worldwide. SGLT2is control glycaemia by triggering glycosuria with simultaneous facilitation of a more ketogenic metabolic profile. Patients therefore are...

Full description

Bibliographic Details
Main Authors: Luka Cavka, Urska Bencak Ferko, Natasa Pitz, Zoranco Trpkovski, Mitja Lainscak
Format: Article
Language:English
Published: Wiley 2021-08-01
Series:ESC Heart Failure
Subjects:
Heart failure
Diabetic ketoacidosis
Euglycaemic diabetic ketoacidosis
SGLT2 inhibitor
Online Access:https://doi.org/10.1002/ehf2.13452

Internet

https://doi.org/10.1002/ehf2.13452

Similar Items